Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07330310 is registered in ClinicalTrials.gov with Joincare Pharmaceutical Group Industry Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Lead sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- March 31, 2026
- Completion date
- November 30, 2027
- Enrollment
- 888 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
chronic obstructive pulmonary disease (copd)